XOMA Royalty Corp.XOMA

$41.89+0.17 (+0.41%)
NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap
$730M
Small-cap
+1004%
2016 — today
10-Year Price
+279%
2016 — today
52-Week Range
$22.89$42.40
Current $41.89· 97%

XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.

Valuation in context

P/E ratio
26.7
Historically pricey
Historically pricey — last 10 years
P/B ratio
6.5
Historically pricey
Historically pricey — last 10 years
EV / EBITDA
15.1
Around average
Around the 10-year average
PEG ratio
0.6
Below average
Below the 10-year average
FCF Yield
0.9%
Historically high
Historically high relative to the last 10 years
Free · No credit card needed

Get alerted when XOMA is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.